DYST 201, a gene therapy targeting the mutated forms of the gene responsible for Huntington’s disease, has shown promising results,…
Articles by Patricia Inácio, PhD
The U.S. Food and Drug Administration (FDA) has given fast track designation to AMT-130, uniQure’s gene therapy candidate…
Genistein, a potent stimulator of cells’ natural “cleaning system” was able to reduce the levels of mutant huntingtin protein…
The U.S. Food and Drug Administration (FDA) has issued a letter of support encouraging sRNAlytics to further develop its…
The U.S. Food and Drug Administration has granted orphan drug designation to MP101, an investigational mitochondrial-targeted neuroprotective agent, to treat…
Several small molecules have been identified by the Alborada Drug Discovery Institute as potential inhibitors to help halt the underlying mechanisms that…
uniQure is launching a Phase 1/2 trial in the United States to evaluate the safety and effectiveness of its…
Asuragen has launched a fast, easy-to-use and reliable diagnostic test, called AmplideX PCR/CE HTT Kit, for Huntington’s disease. The AmplideX…
While transplanted fetal nerve cells can survive long term in the brain of a Huntington’s disease (HD) patient, only…
A bioactive compound present in raspberries called salidroside can prevent the cellular toxicity that occurs as a consequence of protein accumulation in…